ArticleCommunications chemistry2025
Spotlighting the criticality of lipid quality control through a mechanistic investigation of mRNA activity loss in lipid nanoparticles.
Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Next-Generation Nanocarrier Platforms for RNA Vaccines: Advances in Formulation, Stability Engineering, and Translational Manufacturing Challenges.Pharmaceutics · 2026Review
- Beyond Permanent Genome Editing: Molecular Delivery Strategies for RNA Editing and Epigenome-Editing Therapeutics.International journal of molecular sciences · 2026Review
- Analytical Characterization and Stability Assessment of RNA-Based Vaccines.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticles (LNPs) have gained much attention after the recent launch of mRNA based Covid vaccines. For mRNA encapsulated within LNPs to be successfully translated into target proteins, the mRNA must maintain its integrity and also be free of any unintended chemical modifications. Any process or raw material related impurities-and their degradation products-pose risks of chemically modifying mRNA, thereby affecting the quality of the final product. Given its inherent chemical reactivity and close association with the LNP lipids, encapsulated mRNA is especially susceptible to modifications by reactive impurity species present in the lipids. In our recent efforts to understand mRNA-lipid interactions within LNPs, we observed that the degradants of labile lipid peroxide species in ionizable lipids react with nucleotides in mRNA, resulting in loss of mRNA's translation efficiency in vitro. Specifically, we identified peroxide species in unsaturated dialkene groups were converted to a variety of reactive aldehyde products in mRNA LNP formulations. These findings enhance the current understanding of the adduct formation between mRNA and aldehyde species, and emphasize the critical role of deep analytical characterization of ionizable lipid stability and purity to enhance LNP product quality and shelf-life.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.